Q517--667-27-1-075-0004- Compounding sterile hazardous chemotherapy agents
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 16, has issued a Notice of Intent to Sole Source for sterile compounding services of hazardous chemotherapy agents. The VA intends to award a Firm-Fixed-Price contract to Optum Infusion Services 308, LLC for contingency services at the Overton Brooks VA Medical Center in Shreveport, LA. Other interested parties are invited to submit capabilities statements. Responses are due April 6, 2026.
Scope of Work
The contractor will provide aseptic compounding of hazardous chemotherapy agents based on patient-specific orders. This includes supplying all necessary agents, IV tubing, and closed system drug transfer devices. Services must be performed at an FDA 503A compliant facility adhering to all state and federal laws, including USP 797 and USP 800 standards. Deliveries of compounded orders must be made via courier or overnight mail to ensure receipt prior to infusion. The contractor must also provide certification reports for sterile compounding areas, a contingency backup plan, and an annual "VHA PBM Template: Evaluation of Outsourced 503A Compounding Pharmacies."
Contract & Timeline
- Type: Notice of Intent to Sole Source (anticipated Firm-Fixed-Price contract)
- Anticipated Awardee: Optum Infusion Services 308, LLC
- Anticipated Award Date: October 1, 2026
- Period of Performance: One base year (Oct 1, 2026 - Sep 30, 2027) with four one-year option periods.
- NAICS Code: 456110 (Pharmacies and Drug Retailers), Size Standard: $37.5 million.
- Response Due: April 6, 2026, 9:00 AM CST
- Published: March 20, 2026
Submission & Evaluation
This is a sole source notice, not a request for competitive quotes. However, interested parties believing they can meet the requirements may submit a capabilities statement providing clear and unambiguous evidence of their ability. Submissions must be emailed to tiffany.conner@va.gov with the subject line "Notice of Intent 36C25626Q0533 Sterile Compounding". Verbal and facsimile responses will not be accepted. If no viable responses are received, NCO 16 will proceed with negotiations solely with Optum Infusion Services 308, LLC.
Additional Notes
Respondents must be registered with the System for Award Management (SAM). The original description also mentioned seeking Service-Disabled Veteran Owned Small Businesses, Veteran Owned Small Businesses, or Small Businesses for market research purposes, though this specific notice is for sole source intent.